• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎:发现临床试验概述

COVID-19: A Brief Overview of the Discovery Clinical Trial.

作者信息

Vanden Eynde Jean Jacques

机构信息

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium.

出版信息

Pharmaceuticals (Basel). 2020 Apr 10;13(4):65. doi: 10.3390/ph13040065.

DOI:10.3390/ph13040065
PMID:32290348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7243102/
Abstract

The outbreak of COVID-19 is leading to a tremendous search for curative treatments. The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and included in the first clinical trial of the European Discovery project.

摘要

新型冠状病毒肺炎疫情引发了对治疗方法的大规模探索。当前形势的紧迫性有利于对现有药物进行重新利用,而不仅仅局限于抗病毒药物。本简短通讯聚焦于世界卫生组织推荐的、并被纳入欧洲发现项目首次临床试验的四种治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7bf/7243102/5f6ea6d6a06d/pharmaceuticals-13-00065-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7bf/7243102/5f6ea6d6a06d/pharmaceuticals-13-00065-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7bf/7243102/5f6ea6d6a06d/pharmaceuticals-13-00065-g001.jpg

相似文献

1
COVID-19: A Brief Overview of the Discovery Clinical Trial.新型冠状病毒肺炎:发现临床试验概述
Pharmaceuticals (Basel). 2020 Apr 10;13(4):65. doi: 10.3390/ph13040065.
2
COVID-19: An Update About the Discovery Clinical Trial.新型冠状病毒肺炎:探索性临床试验的最新情况
Pharmaceuticals (Basel). 2020 May 14;13(5):98. doi: 10.3390/ph13050098.
3
Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review.探索现有药物在新冠疫情管理中的再利用潜力:一项批判性综述。
J Clin Med Res. 2020 Aug;12(8):463-471. doi: 10.14740/jocmr4241. Epub 2020 Jul 22.
4
The journey of remdesivir: from Ebola to COVID-19.瑞德西韦的历程:从埃博拉到新冠病毒。
Drugs Context. 2020 May 22;9. doi: 10.7573/dic.2020-4-14. eCollection 2020.
5
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.新冠疫情时代的药物重新利用:来自显示制药特性的案例研究的见解
Pharmaceutics. 2021 Feb 25;13(3):302. doi: 10.3390/pharmaceutics13030302.
6
Emerging Therapeutic Strategies for COVID-19 patients.针对新冠肺炎患者的新兴治疗策略
Discoveries (Craiova). 2020 Mar 12;8(1):e105. doi: 10.15190/d.2020.2.
7
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements.2019冠状病毒病大流行中药物重新利用面临的挑战。关于潜在新改进措施的讨论。
Front Pharmacol. 2020 Oct 28;11:559996. doi: 10.3389/fphar.2020.559996. eCollection 2020.
8
Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19.《瑞德西韦的修正:对其发现与研发历程的回顾,该历程导向了针对治疗 COVID-19 的人体临床试验》
ACS Cent Sci. 2020 Jun 24;6(6):1009. doi: 10.1021/acscentsci.0c00747. Epub 2020 Jun 16.
9
Covid-19: Remdesivir has little or no impact on survival, WHO trial shows.世界卫生组织的试验表明:新冠疫情下,瑞德西韦对存活率几乎没有影响。
BMJ. 2020 Oct 19;371:m4057. doi: 10.1136/bmj.m4057.
10
Covid-19: UK launches antivirals taskforce to deliver home treatments by autumn.新冠疫情:英国启动抗病毒药物特别工作组,以便在秋季前提供居家治疗方案。
BMJ. 2021 Apr 26;373:n1077. doi: 10.1136/bmj.n1077.

引用本文的文献

1
Rapidly Evolving SARS-CoV-2: A Brief Review Regarding the Variants and their Effects on Vaccine Efficacies.快速演变的严重急性呼吸综合征冠状病毒2:关于变异株及其对疫苗效力影响的简要综述
Infect Disord Drug Targets. 2024;24(4):58-66. doi: 10.2174/0118715265271109231129112515.
2
Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?探索针对 SARS-CoV-2 及其变体的 COVID-19 候选疫苗:我们的立场在哪里,我们的前进方向在哪里?
Hum Vaccin Immunother. 2021 Dec 2;17(12):4714-4740. doi: 10.1080/21645515.2021.1995283.
3
Covid-19 vaccines and variants of concern: A review.

本文引用的文献

1
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者,没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19:一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
3
Covid-19 疫苗和关注变种:综述。
Rev Med Virol. 2022 Jul;32(4):e2313. doi: 10.1002/rmv.2313. Epub 2021 Nov 9.
4
COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?新冠病毒肺炎:“发现”临床试验失败,新希望何在?
Pharmaceuticals (Basel). 2021 Jul 11;14(7):664. doi: 10.3390/ph14070664.
5
Antiviral peptides from aquatic organisms: Functionality and potential inhibitory effect on SARS-CoV-2.来自水生生物的抗病毒肽:对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的功能及潜在抑制作用
Aquaculture. 2021 Aug 30;541:736783. doi: 10.1016/j.aquaculture.2021.736783. Epub 2021 Apr 15.
6
Binding ability of arginine, citrulline, -acetyl citrulline and thiocitrulline with SARS COV-2 main protease using molecular docking studies.利用分子对接研究精氨酸、瓜氨酸、α-乙酰瓜氨酸和硫代瓜氨酸与新型冠状病毒2型主要蛋白酶的结合能力。
Netw Model Anal Health Inform Bioinform. 2021;10(1):28. doi: 10.1007/s13721-021-00301-x. Epub 2021 Apr 6.
7
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.重新定位 HIV 蛋白酶抑制剂和核苷(酸)RNA 聚合酶抑制剂以治疗 SARS-CoV-2 感染和 COVID-19。
Eur J Clin Pharmacol. 2021 Sep;77(9):1297-1307. doi: 10.1007/s00228-021-03108-x. Epub 2021 Mar 4.
8
In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.基于结构的 SARS-CoV-2 主蛋白酶和聚合酶抑制剂的计算机预测:3D 药效团模型。
J Biomol Struct Dyn. 2022 Sep;40(14):6569-6586. doi: 10.1080/07391102.2021.1886991. Epub 2021 Feb 18.
9
COVID-19-Associated Hyper-Fibrinolysis: Mechanism and Implementations.新型冠状病毒肺炎相关的高纤维蛋白溶解:机制与应用
Front Physiol. 2020 Dec 16;11:596057. doi: 10.3389/fphys.2020.596057. eCollection 2020.
10
Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.利托那韦可能会抑制 SARS-CoV-2 病毒 nsp14 的外切核酸酶活性,并增强链终止药物的活性。
Int J Biol Macromol. 2021 Jan 31;168:272-278. doi: 10.1016/j.ijbiomac.2020.12.038. Epub 2020 Dec 9.
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
4
Covid-19 - The Search for Effective Therapy.新冠病毒-19:寻找有效疗法
N Engl J Med. 2020 May 7;382(19):1851-1852. doi: 10.1056/NEJMe2005477. Epub 2020 Mar 18.
5
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
6
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.严重急性呼吸综合征相关冠状病毒:将 2019-nCoV 进行分类并命名为 SARS-CoV-2。
Nat Microbiol. 2020 Apr;5(4):536-544. doi: 10.1038/s41564-020-0695-z. Epub 2020 Mar 2.
7
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.洛匹那韦疗法治疗严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒的系统评价——为新型冠状病毒病治疗方案提供参考。
J Med Virol. 2020 Jun;92(6):556-563. doi: 10.1002/jmv.25729. Epub 2020 Mar 12.
8
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.突破:磷酸氯喹在临床研究中显示出对 COVID-19 相关肺炎的明显疗效。
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
9
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.预防性和治疗性瑞德西韦(GS-5734)治疗中东呼吸综合征冠状病毒感染恒河猴模型。
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776. doi: 10.1073/pnas.1922083117. Epub 2020 Feb 13.
10
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒(2019 - 新冠病毒)。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.